Cambridge, MA, United States
Cambridge, MA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Blueprint Medicines | Date: 2017-04-04

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.


Patent
Blueprint Medicines | Date: 2017-05-24

FGR (feline Gardner-Rasheed sarcoma viral oncogene homolog) fusions are described herein. Further provided are methods of diagnosing and treating diseases or disorders associated with FGR fusions, such as conditions mediated by FGR aberrant activity, or overexpression.


Patent
Blueprint Medicines | Date: 2017-05-24

The invention provides TERT gene fusions, TERT fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing diseases or disorders associated with TERT fusions, such as conditions mediated by aberrant TERT expression or activity, or overexpression of TERT.


Patent
Blueprint Medicines | Date: 2016-08-26

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.


Patent
Blueprint Medicines | Date: 2016-04-13

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.


Patent
Blueprint Medicines | Date: 2017-02-22

The invention provides MET gene fusions, MET fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with MET fusions, such as conditions mediated by aberrant MET expression or activity or overexpression of MET.


Patent
Blueprint Medicines | Date: 2017-02-22

The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic suhunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by P1K3CA aberrant expression or activity, or overexpression of P1K3CA.


Patent
Blueprint Medicines | Date: 2017-05-24

The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.


Patent
Blueprint Medicines | Date: 2017-04-19

The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.


Patent
Blueprint Medicines | Date: 2017-04-19

The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.

Loading Blueprint Medicines collaborators
Loading Blueprint Medicines collaborators